{"id":"W4319341650","doi":"10.1158/1078-0432.ccr-22-3298","title":"Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics","year":2023,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Janssen Pharmaceuticals; Loxo Oncology; Genentech; Sierra Oncology; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Generalitat de Catalunya; Fundación Científica Asociación Española Contra el Cáncer; MacroGenics; Menarini Group; F-star Therapeutics; Banco Bilbao Vizcaya Argentaria; BeiGene; Agios Pharmaceuticals; Merck KGaA; Regeneron Pharmaceuticals; Les Laboratories Pierre Fabre; Principia Biopharma; Fundació la Marató de TV3; Fundación BBVA; Symphogen; Pfizer; Incyte; F. Hoffmann-La Roche; Ministerio de Ciencia e Innovación; European Commission; Sanofi; Centres de Recerca de Catalunya; GlaxoSmithKline; Instituto de Salud Carlos III; Amgen; Celgene; Agència de Gestió d'Ajuts Universitaris i de Recerca; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Antigen; Immunosurveillance; Immunogenicity; Cancer; Cancer research; Biology; T cell; Cancer immunotherapy; Immune system; Immunology; Immunotherapy; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00770434,0.000512344,0.001418186,0.0002744245,0.0008187126,0.00009570258,0.002804521,0.001312967,0.001206795],"category_scores_gemma":[0.001976763,0.0003636477,0.001052023,0.0009558258,0.003801897,0.0002039491,0.001161995,0.01167095,0.001785391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002486954,"about_ca_system_score_gemma":0.001963214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003079881,"about_ca_topic_score_gemma":0.00006359537,"domain_scores_codex":[0.9909474,0.00378692,0.002110461,0.001074611,0.0004577762,0.001622806],"domain_scores_gemma":[0.9874442,0.009102389,0.0005893512,0.002124504,0.0007088491,0.00003067318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.005220617,0.0002461242,0.0002883288,0.0003023466,0.002887119,0.0002016771,0.001005819,0.000002412113,0.04314658,0.0001117874,0.9359577,0.01062944],"study_design_scores_gemma":[0.001706209,0.0007459276,0.004037056,0.00048958,0.0001189322,0.00003400078,0.0002687874,5.605073e-7,0.07445557,0.0002474594,0.917467,0.0004289349],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7347168,0.04102197,0.00001435842,0.2063937,0.01357068,0.003023422,0.0005278467,0.0001957506,0.0005354905],"genre_scores_gemma":[0.3060853,0.1366968,0.0000961707,0.2526455,0.02009413,0.01753921,0.00166863,0.001679406,0.2634949],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4286315,"threshold_uncertainty_score":0.9999835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5256608444183113,"score_gpt":0.4866425423422372,"score_spread":0.0390183020760741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}